Eli Lilly combo boasts best study results for a COVID-19 therapy so far

Results from a new study released this week showed that an Eli Lilly antibody therapy combo cut the risk of hospitalizations and death from COVID-19 by 87 percent. 

The study of the bamlanivimab and etesevimab combo involved more than 750 high-risk patients.

This is the second large study of the combo on COVID-19 patients, but this time, the antibodies performed better. In January, a study of a higher dose of the combo showed that it could reduce the risk of hospitalizations by 70 percent.

The treatments have already been given an EUA in the U.S. to treat patients with mild to moderate COVID-19, but Lilly hopes that the positive results from the recent study will help boost more use of the therapies. Lilly also says that the combo provides protection against emerging variants of COVID-19 currently in the U.S.

The U.S. has already struck a deal to purchase 100,00 doses of the combo treatment and Lilly is planning to crank out 1 million doses within the next few months.

Read the Reuters report.